Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of United Therapeutics Corp (NASDAQ: UTHR) closed at $484.1 in the last session, up 0.65% from day before closing price of $480.96. In other words, the price has increased by $0.65 from its previous closing price. On the day, 0.63 million shares were traded. UTHR stock price reached its highest trading level at $485.36 during the session, while it also had its lowest trading level at $477.56.
Ratios:
We take a closer look at UTHR’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.58. For the most recent quarter (mrq), Quick Ratio is recorded 6.07 and its Current Ratio is at 6.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Underweight rating and assigned the stock a target price of $414.
On September 26, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $569.
On June 02, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $405.Cantor Fitzgerald initiated its Overweight rating on June 02, 2025, with a $405 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when ROTHBLATT MARTINE A bought 4,000 shares for $480.01 per share.
ROTHBLATT MARTINE A bought 4,000 shares of UTHR for $1,901,088 on Dec 03 ’25. On Dec 01 ’25, another insider, EDGEMOND JAMES, who serves as the CFO AND TREASURER of the company, sold 21,000 shares for $479.99 each. As a result, the insider received 10,079,696 and left with 8,142 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, UTHR now has a Market Capitalization of 21894035456 and an Enterprise Value of 18076098560. As of this moment, United’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.35, and their Forward P/E ratio for the next fiscal year is 15.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.66 while its Price-to-Book (P/B) ratio in mrq is 3.15. Its current Enterprise Value per Revenue stands at 5.778 whereas that against EBITDA is 11.269.
Stock Price History:
The Beta on a monthly basis for UTHR is 0.84, which has changed by 0.30105233 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, UTHR has reached a high of $492.62, while it has fallen to a 52-week low of $266.98. The 50-Day Moving Average of the stock is 7.45%, while the 200-Day Moving Average is calculated to be 38.65%.
Shares Statistics:
According to the various share statistics, UTHR traded on average about 658.16K shares per day over the past 3-months and 388170 shares per day over the past 10 days. A total of 42.90M shares are outstanding, with a floating share count of 41.53M. Insiders hold about 3.54% of the company’s shares, while institutions hold 96.10% stake in the company. Shares short for UTHR as of 1763078400 were 1650438 with a Short Ratio of 2.51, compared to 1760486400 on 2033908. Therefore, it implies a Short% of Shares Outstanding of 1650438 and a Short% of Float of 5.11.
Earnings Estimates
The dynamic stock of United Therapeutics Corp (UTHR) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $7.02, with high estimates of $7.95 and low estimates of $6.06.
Analysts are recommending an EPS of between $28.98 and $25.17 for the fiscal current year, implying an average EPS of $27.1. EPS for the following year is $28.49, with 13.0 analysts recommending between $32.44 and $24.47.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $818.74M. It ranges from a high estimate of $856.4M to a low estimate of $779.4M. As of. The current estimate, United Therapeutics Corp’s year-ago sales were $735.9MFor the next quarter, 11 analysts are estimating revenue of $817.94M. There is a high estimate of $849M for the next quarter, whereas the lowest estimate is $792.1M.
A total of 13 analysts have provided revenue estimates for UTHR’s current fiscal year. The highest revenue estimate was $3.25B, while the lowest revenue estimate was $3.15B, resulting in an average revenue estimate of $3.21B. In the same quarter a year ago, actual revenue was $2.88BBased on 13 analysts’ estimates, the company’s revenue will be $3.39B in the next fiscal year. The high estimate is $3.55B and the low estimate is $3.09B.
